Edoardo Pennesi

Edoardo Pennesi

Princess Maxima Centre for Pediatric Oncology - / Netherlands
Others
AD Scientific Index ID: 5570760
Prinses Maxima Centrum voor Kinderoncologie
person_outline Edoardo Pennesi's MOST POPULAR ARTICLES
1-) Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trialE Pennesi, N Michels, E Brivio, VHJ van der Velden, Y Jiang, A Thano, ...Leukemia 36 (6), 1516-1524, 2022352022
2-) A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC …E Pennesi, E Brivio, ME Willemse, ADR Huitema, S Chandra, ...Blood 138, 2558, 202142021
3-) Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: results from the phase I part of study ITCC054/COG AAML1921E Brivio, E Pennesi, ME Willemse, ADR Huitema, Y Jiang, ...Journal of Clinical Oncology 42 (7), 821-831, 202442024
4-) Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trialE Pennesi, E Brivio, ACJ Ammerlaan, Y Jiang, VHJ Van der Velden, ...Haematologica, 202042020
5-) Inotuzumab Ozogamicin (InO) combined with UKALL-R3 modified chemotherapy in pediatric patients with B-cell precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL)-results from …E Pennesi, E Brivio, ACJ Ammerlaan, Y Jiang, VHJ van der Velden, ...Blood 140 (Supplement 1), 8976-8978, 202232022